Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

CONCLUSION: Based on the FAERS database, this study identifies significant pharmacovigilance signals and potential reporting-associated factors for ipilimumab, nivolumab, and their combination. Importantly, these findings represent hypothesis-generating signal detections rather than definitive causal risk estimations, underscoring the absolute necessity for heightened clinical vigilance and routine endocrinological monitoring. These findings inform clinical monitoring strategies and provide a...